ReproCELL Inc. (JP:4978)

:4978

4978

ReproCELL Inc.

RESEARCH TOOLSreports

Want to see JP:4978 full AI Analyst Report?

ReproCELL Inc. (4978) Price & Analysis

0 Followers

4978 Stock Chart & Stats

¥143.00

¥3.00(2.91%)

At close: Jan 08 4:00 PM EST

¥143.00

¥3.00(2.91%)

Day’s Range― - ―

52-Week Range¥121.00 - ¥242.00

Previous CloseN/A

Volume331.50K

Average Volume (3M)510.74K

Market Cap

¥12.27B

Enterprise Value¥9.66B

Total Cash (Recent Filing)¥4.72B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta0.56

Next Earnings

Aug 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.32

Shares Outstanding95,147,890

10 Day Avg. Volume504,660

30 Day Avg. Volume510,736

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)1.88

Price to Sales (P/S)7.46

P/FCF Ratio-34.60

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)1.7

Revenue Forecast (FY)¥3.53B

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthEffectively zero debt and a sizeable equity base create a durable capital buffer that lowers insolvency risk and preserves strategic optionality. Over the next 2–6 months this reduces refinancing pressure, supports R&D and contract-service continuity, and cushions against revenue volatility.

Solid Gross ProfitSustained absolute gross profit above ¥1.0B indicates the core product/service mix generates meaningful value and unit economics. If operating expenses are managed, this underlying margin provides a pathway to restore operating profitability and scalable cash generation over the medium term.

Niche In IPSC/regenerative FieldConcentration on iPSC and regenerative-medicine tools targets a structural growth area in drug discovery and cell biology research. This specialized positioning supports recurring demand from academic and pharma customers and underpins longer-term revenue opportunities tied to the expanding stem-cell research ecosystem.

Bears Say

Persistent Cash BurnConsistent negative operating and free cash flow means the business is not self-funding; over months this forces reliance on external financing or equity, constraining capital allocation. Persistent cash burn undermines sustainability and can dilute shareholders or limit investments if not reversed.

Volatile Revenue And Recent DeclineMaterial top-line volatility and a sharp 2026 revenue decline reduce predictability for capacity, hiring, and R&D planning. This variability weakens margin leverage, complicates contract-service scaling, and increases the odds that shortfalls persist absent durable demand recovery or diversification.

Operating Cost PressureDespite solid gross profit, operating costs consistently erode profitability, indicating structural cost or business-model inefficiencies. Even a year of net income failed to produce positive free cash flow, highlighting a lasting disconnect between accounting profit and cash conversion.

4978 FAQ

What was ReproCELL Inc.’s price range in the past 12 months?

ReproCELL Inc. lowest stock price was ¥121.00 and its highest was ¥242.00 in the past 12 months.

What is ReproCELL Inc.’s market cap?

ReproCELL Inc.’s market cap is ¥12.27B.

When is ReproCELL Inc.’s upcoming earnings report date?

ReproCELL Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 56 days.

How were ReproCELL Inc.’s earnings last quarter?

ReproCELL Inc. released its earnings results on May 14, 2026. The company reported -¥1.4 earnings per share for the quarter, missing the consensus estimate of N/A by -¥1.4.

Is ReproCELL Inc. overvalued?

According to Wall Street analysts ReproCELL Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ReproCELL Inc. pay dividends?

ReproCELL Inc. does not currently pay dividends.

What is ReproCELL Inc.’s EPS estimate?

ReproCELL Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ReproCELL Inc. have?

ReproCELL Inc. has 95,147,890 shares outstanding.

What happened to ReproCELL Inc.’s price movement after its last earnings report?

ReproCELL Inc. reported an EPS of -¥1.4 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.775%.

Which hedge fund is a major shareholder of ReproCELL Inc.?

Currently, no hedge funds are holding shares in JP:4978

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ReproCELL Inc.

Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, including a diverse array of specialized reagents for RNA reprogramming, cell growth (such as small molecules, growth factors, and cytokines), cell characterization (like antibodies and staining kits), cell culture (including pluripotent stem cell media and cell substrates), and cell handling (such as cryopreservation media, dissociation solutions, and transfection reagents). Furthermore, ReproCELL provides differentiated induced pluripotent stem cells (iPSCs), related components like feeder cells and induced neurons, 3D cell culture systems, and general laboratory consumables. Complementing its product lines, the company offers a comprehensive suite of services, spanning preclinical genomics, dedicated stem cell research, drug development support (encompassing efficacy, safety, and ADME analyses), access to human tissue samples, therapeutic pipeline development, and a range of clinical services, including laboratory diagnostics and the creation of GMP iPSC master cell banks.